AACR Data Highlights InNexus Preclinical Antibody Candidate

    - Additional Presentations Underscore Potency, Binding Capabilities for
Antibody Pipeline And Novel Technologies -

    SCOTTSDALE, Ariz., April 9 /PRNewswire-FirstCall/ -- InNexus
Biotechnology Inc. (Toronto Stock Exchange: IXS.V, http://www.ixsbio.com), a
drug development company commercializing the next generation of monoclonal
antibodies based on its technology, Dynamic Cross Linking (DXL(TM)), announced
today that the company will be presenting new data on its lead preclinical
candidate DXL625 (CD20) for the prospective treatment of Non Hodgkin's
Lymphoma (NHL) at the annual meeting of the American Association for Cancer
Research (AACR), April 18-22, in Denver.

    "Preclinical data on DXL625 indicates the strong promise of this
candidate as a prospective treatment for NHL and Chronic Lymphatic Leukemia
(CLL), and we anticipate starting clinical trials in the near term," said Dr.
Thomas Kindt, Chief Scientific Officer of InNexus.  "The AACR will also
feature a scientific presentation on our novel, proprietary approach for
creating 'programmed' self-binding properties into antibodies.  The increased
potency of the antibody resulting from this technique suggests a new way to
enhance antibody performance."

    Jeff Morhet, Chairman and Chief Executive Officer of InNexus, said,
"InNexus has executed a focused and accelerated development plan for DXL625,
while efficiently discovering promising new therapeutic candidates and
supportive technologies.  InNexus remains a novel, and independent,
'pure-play' antibody development company--an unusual investment and commercial

    InNexus' AACR presentations are titled, "A Novel High Avidity Anti-CD20
With Markedly Increased Cytotoxicity Shows No Systemic Toxicity In The
Cynomolgus Monkey At A Dose 100-Fold Above The Anticipated Therapeutic Dose",
(AACR# 1231) and "Oxidative Modification Of An Anti-CD20 Antibody Imparts
Autophilic Binding Kinetics", (AACR# 1230).  Posters and company
representatives will also be available within the AACR Antibody and Antibody
Targets Session from 1:00-5:00 PM on April 19th in Hall B-F, Poster Section
12.  The posters will also be available via the InNexus website beginning
April 19th.

    About InNexus

    InNexus is a drug development company commercializing the next generation
of monoclonal antibodies based on its DXL technology, which improves the
potency of existing antibody products while opening new markets and disease
applications. DXL antibodies utilize unique, novel and patented methods and
technologies of InNexus.

    InNexus is headquartered in British Columbia with principal management
based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own
in-house developmental facilities. These development resources provide
validation of protein and peptide discoveries, enabling InNexus (and its
strategic partners) to advance novel drug therapeutics and diagnostics. To
learn more about InNexus, please visit www.ixsbio.com.

    The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this news release. This news
release may contain assumptions, estimates, and other forward-looking
statements that involve inherent risks and uncertainties and are subject to
factors, many of which are beyond the Company's control, which may cause
actual results or performance to differ materially from those currently
anticipated in such statements.


For further information:

For further information: Jeff Morhet, Chairman & Chief Executive
Officer, or Dr. Thomas Kindt, Chief Scientific Officer, both of InNexus
Biotechnology Inc., +1-480-862-7500 Web Site: http://www.ixsbio.com

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890